ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 22nd World Congress on Gastrointestinal Cancer

 

1-4 July 2020 Barcelona
Close
N. Poster
Poster title
Applicant name
Status
  O-001 PanCO: Updated Results of an Open-Label, Single-Arm Pilot Study of OncoSil P-32 Microparticles in Unresectable Locally Advanced Pancreatic Adenocarcinoma (LAPC) With Gemcitabine Nab-Paclitaxel or FOLFIRINOX Chemotherapy David Turner Received Received
  LBA-001 First-line liposomal irinotecan 5 fluorouracil/leucovorin oxaliplatin in patients with pancreatic ductal adenocarcinoma: Primary analysis from a phase 1/2 study Amie Hedges Received Received
  P-001 LINC00184 promotes the stemness and chemoresistance of gastric cancer by interacting with YAP and by promoting exosomes-mediated macrophage M2 polarization Haiyan Piao Received Received
  SO-001 Prognostic nomogram to predict overall survival in patients with unresectable pancreatic cancer treated with gemcitabine plus nab-paclitaxel or FOLFIRINOX: Real-world results from the multicenter retrospective study (NAPOLEON study) Taro Shibuki Received Received
  P-002 An update on the trends for hepatic cancer subtypes in the Philippines, 2003-2012: A population-based study Jansen Cambia Received Received
  PD-002 Role of pretreatment SUVmax on 18F-FDG PET and clinicopathological features in the prognostic stratification of newly diagnosed intrahepatic cholangiocarcinoma Alessandro Rizzo Received Received
  LBA-003 CheckMate 459: Long-Term Efficacy Outcomes With Nivolumab Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma Onaisa Rizki Received Received
  SO-003 Maintenance olaparib in patients aged &8805; 65 years with a germline BRCA mutation and metastatic pancreatic cancer: Phase 3 POLO trial Hedy Kindler Received Received
  P-003 Features of metabolic profiles of blood serum and erythrocyte membranes associated with metastasis in colorectal cancer Margarita Kruchinina Received Received
  LBA-004 Updated analysis of DELIVER trial (JACCRO GC-08): A large observational/translational study of nivolumab treatment in advanced gastric cancer YU SUNAKAWA Received Received
  LBA-005 ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600Emutant metastatic colorectal cancer Axel Grothey Received Received
  O-005 Efficacy and safety of nivolumab ipilimumab in Asian patients with advanced hepatocellular carcinoma: subanalysis of the CheckMate 040 study Onaisa Rizki Received Received
  PD-005 Impact of biliary drainage for unresectable pancreatic cancer treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel: Results from the NAPOLEON study Takuya Honda Received Received
  P-005 Economic Burden of HCC And The Need Of Innovative Treatments Abdalla Abotaleb Received Received
  SO-006 The influence of liver function on the outcomes of phase II trial of sorafenib vs. hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma Satoshi Kobayashi Received Received
  P-006 Perioperative FLOT: Tolerability, pathological response rates, and the role of adjuvant phase ERCAN ZDEN Received Received
  PD-006 Gemcitabine nab-paclitaxel or gemcitabine alone after FOLFIRINOX failure in patients with metastatic pancreatic adenocarcinoma: a population-based, multicenter AGEO study Sonia Zaibet Received Received
  O-006 The novel regimen of tremelimumab in combination with durvalumab provides a favorable safety profile and clinical activity for patients with advanced hepatocellular carcinoma Bruno Sangro Received Received
  LBA-007 Encorafenib Plus Cetuximab With or Without Binimetinib for BRAFV600E Metastatic Colorectal Cancer (mCRC): Relationship Between Carcinoembryonic Antigen (CEA) and Clinical Outcomes From BEACON CRC Kristen Senn Received Received
  PD-007 Updated survival analysis of the Danish randomized study comparing trifluridine/tipiracil with or without bevacizumab in patients with chemo-refractory metastatic colorectal cancer Per Pfeiffer Received Received
  P-007 Induction chemotherapy in locally advanced rectal cancer: Retrospective report of efficacy and safety in an Argentinean university institution, a feasibility perspective M. Celeste Diaz Received Received
  SO-007 Efficacy and safety of transarterial chemoembolization (TACE) plus apatinib as compared with TACE alone for recurrent hepatocellular carcinoma: A prospective randomized controlled trial Huiying Gu Received Received
  P-008 Risk factors of severe gastric dysplasia and gastric cancer in rural areas of China among individuals at high-risk: A population-based, cross-sectional study Maomao Cao Received Received
  O-008 Atezolizumab bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150 Daneng Li Received Received
  SO-009 Outcomes for patients with advanced hepatocellular carcinoma and Child-Pugh B liver function in the phase 3 CELESTIAL study of cabozantinib vs placebo Donna Stefanoni Received Received
  P-009 A randomized study of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 as first-line treatment for unresectable metastatic colorectal cancer Said Belhadef Received Received
  P-010 Epidemiological and histopathological review of colorectal cancer in Tunisia sonia Ben Nasr Received Received
  PD-010 Improvement of Asia-Pacific colorectal screening score combined with fecal immunochemical testing at adjusted thresholds in colorectal cancer screening Ming Lu Received Received
  P-011 Impact of preoperative and postoperative variation of CEA in predicting nonmetastatic colorectal cancer recurrence. sonia Ben Nasr Received Received
  PD-011 Impact of baseline symptom burden as assessed by patient-reported outcomes on overall survival of patients with metastatic gastrointestinal cancer Atul Batra Received Received
  PD-012 Clinical, pathological and molecular profiles of G3 neuroendocrine tumors and neuroendocrine carcinomas Rodrigo Taboada Received Received
  P-012 A descriptive analysis of patient characteristics from Russian internet postings focused on CRC (iPatient study) Alexandr Krotkevich Received Received
  P-013 Current and expected future profile changes of gastric and pancreatic cancer patients at presentation Rasha Aboelhassan Received Received
  O-014 Young adults with neuroendocrine tumors present a high rate of pathogenic or likely pathogenic germline variants in cancer-predisposing genes Rachel Riechelmann Received Received
  P-014 Dose escalated short-course radiotherapy in rectal cancers: Is this the way forward? Deep Chakrabarti Received Received
  SO-015 Radiomic signature for prediction of peritoneal disseminations in gastric cancer which were not detected by routine CT examinations Sayuri Konishi Received Received
  P-15 Combined Gastrectomies: Survival Outcomes in Patients with Local Advanced Gastric Cancer Oleg Kshivets Received Received
  P-017 Peri-operative FLOT: West of Scotland regional experience Katharine Welsh Received Received
  SO-018 Single-arm multicentre phase II study of bevacizumab (B) combined with 9-weekly alternating CAPOX and CAPIRI as first-line treatment of patients with metastatic colorectal cancer (mCRC): Main results of the AXOAXI-trial Pia Osterlund Received Received
  P-018 REMARRY and PURSUIT trials: Liquid biopsy-guided re-challenge of anti-EGFR monoclonal antibody for patients with RAS/BRAF V600E wild-type metastatic colorectal cancer Hiromichi Nakajima Received Received
  O-018 Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study Carlotta Antoniotti Received Received
  O-019 Feasibility of switching to S-1 upon other fluoropyrimidine-related cardiotoxicity during chemotherapy for solid tumors Pia Osterlund Received Received
  P-019 Role of percutaneous radiofrequency ablation in unresectable, non-metastatic intrahepatic cholangiocarcinoma: A single-institution experience Alessandro Rizzo Received Received
  SO-020 Consensus molecular subtypes and CRCAssigner classifications in metastatic colorectal cancer (mCRC): Prognostic and predictive impact in the TRIBE2 study BEATRICE BORELLI Received Received
  P-020 Identification of predictive biomarkers in colorectal adenocarcinoma Lyudmila Akhmaltdinova Received Received
  P-021 Stereotactic body radiation therapy for locally advanced pancreatic cancer Maria Veronica Vera Merino Received Received
  SO-021 Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer (The BEACON CRC Study) Kristen Senn Received Received
  O-021 METABEAM study: Combined analysis of concordance studies between liquid and tissue biopsies for RAS mutations in colorectal cancer patients with single metastatic sites Yoshinori Kagawa Received Received
  SO-022 Atypical non-V600E BRAF (aBRAF) mutations as a prognostic and predictive factor in real-life metastatic colorectal cancer patients from the Nordic countries Emerik Osterlund Received Received
  P-022 Efficacy of sorafenib in treatment of advanced hepatocellular carcinoma in the Mexican population: Evidence from a third level hospital in Mexico abdel dip Received Received
  P-023 Microwave ablation versus radiofrequency ablation in BCLC-A hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials Alessandro Rizzo Received Received
  SO-024 AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial John Strickler Received Received
  P-024 Neutrophil and lymphocyte ratio as a prognostic biomarker in pancreatic cancer Francine Luiz Received Received
  P-025 Single-institution experience of total neoadjuvant therapy for locally advanced rectal cancer: Long-term results Roberto Milazzotto Received Received
  SO-025 A multicenter phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer: BRAVERY study (EPOC1701) Toshiki Masuishi Received Received
  P-026 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophageal junction adenocarcinoma Markus Moehler Received Received
  P-027 Retrospective observational analysis of p53 mutational status as a prognostic factor in TAS-102 treated metastatic colorectal cancer patients Riccardo Giampieri Received Received
  P-028 Impact of p-mTOR expression on molecular-guided therapy strategies in therapy-refractory metastatic pancreatic ductal adenocarcinoma Hossein Taghizadeh Received Received
  P-029 Molecular profiling of neuroendocrine tumors Alina Isiangulova Received Received
  P-030 Survival benefit of surgical resection after first-line triplet chemotherapy and bevacizumab in patients with initially unresectable metastatic colorectal cancer Mahmoud Elshenawy Received Received
  SO-031 Centralization of care leads to optimal ion and outcomes for patients with peritoneal metastases of colorectal cancer: The Catalonian regional program experience Maria Isabel Ramos Received Received
  P-033 Regorafenib and trifluridine/tipiracil efficacy and safety in chemorefractory metastatic colorectal cancer patients: A single Bulgarian centre retrospective study Nikolay Conev Received Received
  SO-033 Clonal ion of RAS mutant metastatic colorectal cancer into RAS wild-type during first-line therapy Alexander Baraniskin Received Received
  P-034 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy Markus Moehler Received Received
  P-035 Prognostic value of ALBI score in patients with hepatocellular carcinoma Child-Pugh A Ana Raquel Monteiro Received Received
  P-036 Prognostic value of tumor laterality and recurrence risk in patients with stage III colon cancer treated with adjuvant chemotherapy Ana Raquel Monteiro Received Received
  P-037 Phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study MASAHITO KOTAKA Received Received
  SO-037 Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stability and microsatellite instability-high, locally advanced rectal cancer (EPOC 1504) SATOSHI YUKI Received Received
  P-038 KEYNOTE-859: A randomized, double-blind, placebo-controlled phase 3 trial of first-line pembrolizumab plus chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma Josep Tabernero Received Received
  P-039 Prognostic impact of the number of administrations of oxaliplatin in the adjuvant treatment of stage III colon cancer Joana Reis Received Received
  P-040 A correlation between BCL-2 modifying factor, p53 and livin gene expressions in cancer colon patients Enas Elkhouly Received Received
  P-041 Understanding the clinical profiles that influence the concordance of RAS mutations between blood and tissue to guide therapy in metastatic colorectal cancer Elena Brozos-Vázquez Received Received
  P-042 Primary malignant melanoma of anorectal region: An institutional experience in AIIMS Patna JAGJIT PANDEY Received Received
  P-043 Ramucirumab effectiveness in patients with advanced gastric cancer or gastro-esophageal junction adenocarcinoma in clinical practice in Spain: Sub-analysis of RAMIS study Maria Ortega Received Received
  P-044 Transcatheter arterial chemoembolization using CDDP without Lipiodol for super-elderly patients with hepatocellular carcinoma Takeshi Aramaki Received Received
  P-045 Applicable value of transanal endoscopic microsurgery for high-risk rectal adenoma and early rectal cancer: Experience from 126 cases Yunhao Li Received Received
  P-046 Advanced colorectal adenoma detection based on altered methylation signal in plasma samples Kristi Kruusmaa Received Received
  P-047 A phase I/II study of pembrolizumab in combination with ibrutinib for advanced, refractory microsatellite stable colorectal cancers Elaine Tan Received Received
  P-048 First evidence for the antitumor activity of nanoliposomal irinotecan in metastatic biliary tract cancer Hossein Taghizadeh Received Received
  P-049 A study of first-line treatments for patients with BRAFV600E mutant metastatic colorectal cancer in a real-life setting: CAPSTAN study Erika Martinelli Received Received
  P-050 Safety and tolerability of regorafenib: A real-life experience Youssif Abo Elseud Received Received
  P-051 Immunoscore in rectal cancer patients receiving radiation followed by mFOLFOX with avelumab Ali Shamseddine Received Received
  P-052 The diagnostic dilemma between chronic pancreatitis and pancreatic cancer Turon Mirzaev Received Received
  P-053 Clinical evaluation of complex treatment of colorectal cancer with liver metastases Marufjon Salokhiddinov Received Received
  P-054 BISQUIT: A randomized phase II study of the administration of prebiotics and probiotics during definitive treatment with chemotherapy-radiotherapy for patients with squamous cell carcinoma of the anal canal Rachel Riechelmann Received Received
  P-055 GASTHER2: Efficacy of adding trastuzumab to standard chemotherapy in patients with advanced HER2-negative gastric cancer and HER2-positive expression in circulating tumor cells Rachel Riechelmann Received Received
  P-056 Importance determination of interleukin-6 in bile and blood in tumours of the bileopancreatoduodenal zone Marufjon Salokhiddinov Received Received
  P-058 Survival and prognostic factors in metastatic gastric cancer: results from a Bangladeshi cohort Md Shuayb Received Received
  P-059 High blood levels of soluble OX40 (CD134), an immune costimulatory molecule, indicate reduced survival in patients with advanced colorectal cancer Ryoichi Sawada Received Received
  P-061 nab-Paclitaxel plus gemcitabine for metastatic pancreatic cancer: Real life Esther Una Cidon Received Received
  P-062 Inferior survival for mismatch repair deficient metastatic colorectal cancer observed in an Irish cohort Alice Talbot Received Received
  P-063 FOLFIRINOX in borderline resectable pancreatic carcinoma Esther Una Cidon Received Received
  P-064 P-in and factor VIII as risk factors of thromboembolic disease in patients with hepatocellular carcinoma Matej Hrncar Received Received
  P-065 Locally advanced/metastatic gastric cancer: Real-world data on first-line treatment with oxaliplatin and cisplatin-based doublets Helena Luna Pais Received Received
  P-066 Treatment with FOLFIRI-aflibercept in an elderly population (over 75 and octogenarians) with metastatic colorectal cancer after failure of an oxaliplatin-based regimen: Experience in a real-life population Gabriella Buccafusca Received Received
  P-067 Short-term outcomes of capecitabine plus oxaliplatin versus S-1 plus oxaliplatin as adjuvant chemotherapies for advance gastric cancer after laparoscopic gastrectomy and D2 resection: A prospective, multicenter randomized, controlled clinical trial Yongjia Yan Received Received
  P-069 Efficacy and safety of S-1 following gemcitabine plus cisplatin for biliary tract cancer Hiroto Inoue Received Received
  P-070 Multimodal treatment in metastatic colorectal cancer improves outcomes: a University College London Hospital experience Nalinie Joharatnam-Hogan Received Received
  P-071 Prognostic biomarkers of therapy by hepatic radioembolization with Ytrio-90 spheres in colorectal liver metastases Eva M Triviño-Ibáñez Received Received
  P-072 Biomarkers of survival and therapeutic response to hepatic radioembolization with Ytrio-90 spheres in hepatocellular carcinoma Eva M Triviño-Ibáñez Received Received
  P-073 Clinical prognostic factors for overall survival and time to progression in RAS-wild type metastatic colorectal cancer treated with anti-EGFR monoclonal antibodies as third or subsequent-line therapy Tomasz Lewandowski Received Received
  P-075 Retrospective comparison between FLOT perioperative chemotherapy vs surgery followed by adjuvant chemotherapy: Results from a multicenter analysis Maria Giuditta Baleani Received Received
  P-076 A phase 1 study of AMG 199, a half-life extended bispecific T-cell engager (HLE BiTE) immune therapy, targeting MUC17 in patients with gastric and gastroesophageal junction cancer Samantha Nguyen Received Received
  P-077 Real-world evidence on second-line treatment of fluoropyrimidine, irinotecan, and anti-VEGF antibody for metastatic colorectal cancer Takeharu Yamanaka Received Received
  P-078 Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies Emma McConnell Received Received
  P-079 C-PRECISE-01 study: A phase Ib/II trial of MEN1611, a PI3K inhibitor, and cetuximab in patients with PIK3CA mutated metastatic colorectal cancer failing irinotecan, oxaliplatin, 5-FU and anti-EGFR containing regimens Marianna Luciana Ferrara Received Received
  P-080 TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma Pascal Hammel Received Received
  P-081 Phase I-II of the update of the EORTC quality of life gastric module QLQ-STO22 Mitsumi Terada Received Received
  P-082 Clinical features of Japanese patients with detailed RAS/BRAF mutant colorectal cancer Hironaga Satake Received Received
  P-083 Pancreatic cancer, treatment options, and sequential therapy: The experience of a district oncology center Alícia Oliveira Received Received
  P-084 Colon cancer in the elderly: A comprehensive assessment of treatment and its outcomes Alícia Oliveira Received Received
  P-086 Comparison of the pharmacokinetics of donafenib and sorafenib in patients with advanced hepatocellular carcinoma: An open-label, randomized, parallel-controlled, multicentre phase II/III trial Feng Bi Received Received
  P-088 A multicenter analysis of the correlation between overall survival and progression-free survival and the number of chemotherapeutic key drugs used in patients with advanced/unresectable pancreatic cancer: Results from the NAPOLEON study Tsuyoshi Shirakawa Received Received
  P-089 Validation of the prognostic significance of the dNLR (2.2) in a population-based cohort of metastatic colorectal cancer patients treated with oxaliplatin-based first-line therapy Juan Ruiz Bañobre Received Received
  P-090 Does the postoperative course of events influence 2-year mortality in patients undergoing hyperthermic intraperitoneal chemotherapy? An evaluation by a novel scoring system Mrudula Tatakuri Received Received
  P-091 A retrospective analysis of maintenance strategies in metastatic gastric and gastroesophageal cancer Daniel Walden Received Received
  P-092 Autophagy drugs are dynamic regulators of long non-coding RNA expression in colorectal cancer Md Zahirul Islam Khan Received Received
  P-093 Levels of steroid hormones, their precursors and ACTH in the blood of patients with pancreatic diseases Olesia Ossovskaya Received Received
  P-094 Predictive assessment of peritoneal spread in patients with gastric cancer Elena Frantsiyants Received Received
  P-095 Non-metastatic anal cancer outcomes: A single-center experience Diana Simão Received Received
  P-096 Levels of sex hormones and sex steroid receptors in pathological tissues in gastric cancer patients Olesia Ossovskaya Received Received
  P-097 Functions of antioxidant enzymes in the blood of patients with pancreatic neuroendocrine tumors Olesia Ossovskaya Received Received
  P-098 HGCSG1902: Multicenter, prospective, observational study for cases with dysgeusia caused by chemotherapy for gastrointestinal cancer Takayuki Ando Received Received
  P-099 Pembrolizumab in combination with gemcitabine and cisplatin for the treatment of advanced biliary tract cancer: Phase 3 KEYNOTE-966 trial in progress Arndt Vogel Received Received
  P-100 Quality of life assessment and reporting in gastric cancer treatment: A systematic review of phase 3 clinical trials published between 2010 and 2019 Angela Dalia Ricci Received Received
  P-102 The impact of a multidisciplinary approach in the management of pancreatic disease BRUNELLA DI STEFANO Received Received
  P-103 The role of primary tumor site as a prognostic factor after resection of colorectal liver metastases: A mono-institutional cohort study. Floriana Camarda Received Received
  P-105 Defining novel regulators of inflammatory signaling in pancreatic cancer Jane Parry Received Received
  P-106 Liver metastasis in colorectal cancer: Management and survival outcomes of liver metastasectomy in a single-center analysis Marta Vilaa Received Received
  P-107 LEAP-012: A randomized, double-blind, phase 3 study of pembrolizumab plus lenvatinib in combination with transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma not amenable to curative treatment Sadahisa Ogasawara Received Received
  P-108 Perioperative chemotherapy in locally advanced, resectable gastric cancer: A single-center experience Marta Vilaa Received Received
  P-109 Global mortality for biliary tract cancer Huifen Wang Received Received
  P-111 Prognostic value of inflammation-based scores for patients treated with FOLFIRINOX or gemcitabine plus nab-paclitaxel Shintaro Nakano Received Received
  P-112 HGCSG1801: A phase II trial of 2nd-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibody Hiroshi Nakatsumi Received Received
  P-113 Supportive medication in advanced biliary tract cancers with ABC-02 regimen joni howells Received Received
  P-114 Cytokines as a prognostic marker of overall survival in pancreatic cancer: A meta-analysis and systematic review Harold Nathan Tan Received Received
  P-115 PEMREC: A phase II study to evaluate safety and efficacy of neo-adjuvant pembrolizumab and radiotherapy in localized microsatellite stable rectal cancer Thibaud Kssler Received Received
  P-116 Impact of the number of harvested lymph nodes on survival in Egyptian patients with gastric cancer: Middle eastern tertiary center experience Hussein Fakhry Received Received
  P-117 Prognostic role of plasmatic exosomal and tissue caveolin-1 in metastatic pancreatic cancer patients Alessandro Bittoni Received Received
  P-118 Gastroenteropancreatic neuroendocrine tumors: Experience of the oncology department of the Oran military hospital Amir Zakaria DJOUNIDI Received Received
  P-119 Special mouthwash and chronology of oral mucositis in previous cycle to prevent future episodes Esther Una Cidon Received Received
  P-120 Prospective observational study monitoring circulating tumor DNA in resectable colorectal cancer patients undergoing radical surgery: GALAXY Study in CIRCULATE-Japan (trial in progress) Hiroki Yukami Received Received
  P-122 Treatment related response of T regulatory cells and cytotoxic lymphocytes in early PDAC Skaiste Tulyte Received Received
  P-123 Outcomes and predictive factors of regorafenib benefit in patients with metastatic colorectal cancer in a real-life setting. Nieves Martinez Lago Received Received
  P-124 Tumor budding and CDX2 as additional prognostic factors in stage II colon cancer Debora Ierinò Received Received
  P-125 Radiomic prediction model for pathological responses of neoadjuvant chemotherapy with S-1 plus oxaliplatin (G-SOX) in clinical stage III gastric cancer Dai Manaka Received Received
  P-126 Markers of tumour inflammation are prognostic for overall survival in patients with advanced pancreatic ductal adenocarcinoma receiving FOLFIRINOX chemotherapy KONSTANTINOS KAMPOSIORAS Received Received
  P-127 Potential mechanism of circRNA 000585 in cholangiocarcinoma Fengming Yi Received Received
  P-128 A novel combination of GEMOX and apatinib in treatment of unresectable or metastatic cholangiocellular carcinoma Fengming Yi Received Received
  P-129 Camrelizumab combined with sorafenib versus sorafenib alone in patients with advanced hepatocellular carcinoma: A retrospective study Qinqin Liu Received Received
  P-130 Short course pelvic radiotherapy for localized and oligometastatic rectal adenocarcinoma: The Mayo Clinic experience Shing Fung Lee Received Received
  P-131 Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Interim analysis of a phase II trial Haeseong Park Received Received
  P-132 Malignant transformation of choledochal cysts: Description of a North African series of 7 cases Anisse Tidjane Received Received
  P-133 Extramural venous invasion detected with an elastin stain is a powerful predictor of cancer-specific mortality in STAGE I-IIIB resected colorectal cancer David Cyr Received Received
  P-134 Total neoadjuvant therapy in locally advanced rectal cancer patients: A tertiary medical center experience Ali Shamseddine Received Received
  P-136 Survey of challenges in access to diagnostics and treatment for neuroendocrine tumor patients (SCAN): Early diagnosis and treatment availability Teodora Kolarova Received Received
  P-137 High rectal cancer: Whats the best treatment? Maria Neves Received Received
  P-138 A comparison of the transcriptomic profiles of matched tissue from primary colorectal cancer and corresponding secondary lung metastases Shelize Khakoo Received Received
  P-140 Targeted NGS panel of epigenetic regulators genes: Application results for gastric cancer patients Alexey Kalinkin Received Received
  P-141 The contribution of white blood cell gene expression in the prediction of gastrointestinal cancer Panagiotis Apostolou Received Received
  P-142 Early gastric cancer: Identification of molecular markers able to distinguish penetrating lesions with different prognosis Chiara Molinari Received Received
  P-143 Lack of expression of CDX2: Prognostic biomarker in stage IV colorectal cancer Adriana Soares Received Received
  P-144 Infigratinib versus gemcitabine plus cisplatin as first-line therapy in patients with advanced cholangiocarcinoma with FGFR2 gene fusions/translocations: Phase 3 PROOF trial Lee Miller Received Received
  P-145 CT-based texture analysis using radiomics for hepatic sinusoidal obstruction syndrome (HSOS) in colorectal cancer patients treated with oxaliplatin containing chemotherapy Kiyotaka Kawaguchi Received Received
  P-146 A genetic custom-made in vivo drug screening platform for colorectal cancer patients Nahuel Villegas Received Received
  P-147 Efficacy and safety data of trifluridine/tipiracil treatment in advanced colorectal cancer based on the experience of Juan Ramón Jiménez Hospital in Huelva María Amor Urbano Received Received
  P-150 Khorana and PROTECHT scores in predicting the risk of venous thromboembolism in pancreatic cancer: Which performed better? Sara Dmaso Received Received
  P-151 The impact of adjuvant chemotherapy regimens in stage II colon cancer (CC) patients Soraia Lobo-Martins Received Received
  P-152 The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients Maria Bensi Received Received
  P-153 Novel ultrasonographic scoring system of sinusoidal obstruction syndrome associated with oxaliplatin-based chemotherapy in patients with gastrointestinal cancer Rika Saito Received Received
  P-154 Actionable targets by tumor genomic profiling in patients with cholangiocarcinoma Lee Miller Received Received
  P-155 Efficacy of somatostatin analogues in the treatment of metastatic and unresectable pancreatic neuroendocrine tumors Rafael Correa Received Received
  P-156 A phase Ib\II study of cetuximab and pembrolizumab in metastatic colorectal cancer Christos Fountzilas Received Received
  P-157 Incidence and survival of intestinal soft tissue sarcoma: A retrospective analysis from SEER Shuai Wang Received Received
  P-158 Clinical impact of oral intake in third-line treatment for advanced gastric cancer TAKATSUGU OGATA Received Received
  P-160 A phase II study of resection followed capecitabine plus oxaliplatin for liver metastasis of colorectal cancer (REX study): Safety analysis Takanori Watanabe Received Received
  P-161 Efficacy of third-line anti-EGFR-based treatment versus regorafenib/TAS-102 (R/T) according to primary tumor site in RAS/BRAF wild-type metastatic colorectal cancer patients raffaella vivolo Received Received
  P-162 Perioperative capecitabine-oxaliplatin chemotherapy in resectable gastric cancer arezki arab Received Received
  P-163 Systemic chemotherapy for previously treated metastatic small bowel ddenocarcinoma Taiko Nakazawa Received Received
  P-164 The role of response as a predictor of improved outcome in advanced pancreatic cancer patients treated with first-line gemcitabine plus nab-paclitaxel marta chiaravalli Received Received
  P-166 Baseline radiomics features in metastatic colorectal cancer: Correlation with metastatic site and clinical-pathological characteristics Annunziato Anghelone Received Received
  P-167 Impact of testosterone on sexual function in women with rectal cancer: A prospective, longitudinal, cohort study Annika Svanstrm Rjvall Received Received
  P-169 A first-in-human Phase Ia/b, open-label, multicentre, dose-escalation study of BI 905711 in patients with advanced gastrointestinal cancers James J. Harding Received Received
  P-170 Understanding patient experience in hepatocellular carcinoma (liver cancer): A qualitative patient interview study Shethah Morgan Received Received
  P-171 Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet REFLECT trial inclusion criteria Takuya Sho Received Received
  P-172 Prognostic factors in metastatic gastric cancer patients Élia Cipriano Received Received
  P-173 The role of maintenance therapy in the first and second lines of treatment of metastatic colorectal cancer Danila Gridnev Received Received
  P-175 Total neoadjuvant treatment versus standard therapy (neoadjuvant radiochemotherapy and adjuvant chemotherapy) of rectal cancer with high-risk factors for local or systemic recurrence Vaneja Velenik Received Received
  P-176 Epidemiology and clinical outcomes of patients with pancreatic tumors discussed in tumor board Juliana Silva Received Received
  P-177 Overall survival of patients with left-sided metastatic colorectal cancer in real life: Experience from University Hospital for Tumors in Zagreb, Croatia Mirjana Pavlovic Received Received
  P-178 Prognostic impact of immune-related adverse events with nivolumab or pembrolizumab monotherapy in patients with advanced gastric cancer: A multicenter retrospective analysis iori motoo Received Received
  P-179 The screening and consensus based on practices and evidence (SCOPE) survey: Results of a real-world survey on metastatic colorectal cancer practice patterns Joanne Franklin Received Received
  P-181 Role of detection and quantification of plasma ctDNA RAS mutations by BEAMing digital PCR in patients with locally advanced and metastatic pancreatic cancer Stefania Gkoura Received Received
  P-182 Understanding biliary tumours: Survival outcomes and prognostic factors in a single center Diogo Silva Received Received
  P-183 Inflammatory Response Prediction of Systemic Therapy Outcome in Metastatic Colorectal Cancer Amer Radwi Received Received
  P-184 A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma Eric Van Cutsem Received Received
  P-185 Dietary factors in gastrointestinal cancers: A hospital-based case-control study tasneef zargar Received Received
  P-186 Introduction of DYPD screening and its impact on treatment decisions: One centres experience Alexander Burnett Received Received
  P-187 Impact on survival of local complications in pancreatic cancer: Experience at the Ramón y Cajal University Hospital (HURyC) María San Román Gil Received Received
  P-188 Safety and efficacy of first-line gemcitabine plus nab-paclitaxel for elderly metastatic pancreatic cancer patients Irene Pecora Received Received
  P-189 Role of radiomics in clinical prognostication and prediction of survival among a cohort of metastatic intrahepatic cholangiocarcinoma Venkata pradeep babu koyyala Received Received
  P-190 A retrospective study of regorafenib versus trifluridine/tipiracil efficacy in chemorefractory metastatic colorectal cancer patients: Multi-institution real-life clinical data Pasquale Vitale Received Received
  P-191 Optimal age to start screening for colorectal cancer in average-risk adults: 50 or 45 years old? Dimitrios Tzilves Received Received
  P-192 ART SCORE in determining the feasibility of TACE in hepatocarcinoma Filipa Macedo Received Received
  P-193 Safety, tolerability, and efficacy of total neoadjuvant therapy for adult patients with locally advanced high-risk rectal adenocarcinoma: Retrospective real-world data from South India Ajoy John Received Received
  P-194 The use of cytoreduction and HIPEC in the treatment of peritoneal carcinomatosis: The experience in Ramón y Cajal University Hospital Jorge Esteban Villarrubia Received Received
  P-195 Treatment outcomes of trifluridine/tipiracil therapy in refractory metastatic colorectal cancer: A single-centre observational study Juraj Prejac Received Received
  P-196 CA 19-9 and CEA as markers of survival in rectal cancer Fatima Aurora Aires Received Received
  P-198 The AST/ALT ratio predicts clinical outcome in pancreatic cancer patients treated with capecitabine and gemcitabine: a single institution experience in the west of Algeria aicha bengueddach Received Received
  P-199 The prognostic and therapeutic impact of microsatellite instability in stage II colon cancer: Medical oncology service chu hassan II fes SOUMIA BERRAD Received Received
  P-200 Bone metastases from colorectal cancer correlate with biological characteristics of primary tumors: A retrospective analysis from a single institution Emilio Francesco Giunta Received Received
  P-201 Neoadjuvant hypofractionated intensity-modulated radiotherapy with a simultaneous integrated boost combined with capecitabine in locally advanced rectal cancer Maria Veronica Vera Merino Received Received
  P-202 Demographics and Clinical Characteristics of Metastatic Colorectal Cancer Patients Treated With a Biosimilar to Bevacizumab Whitney Rhodes Received Received
  P-203 Restaging rectal cancer after neoadjuvant chemoradiation therapy: Is magnetic resonance imaging accurate enough? Rita Félix Soares Received Received
  P-204 C60 fullerene inhibits hepatocellular carcinoma development and metastasis: in vitro and in vivo studies Halyna Kuznietsova Received Received
  P-205 Could chemotherapy still be useful in Hepatocarcinoma? Experience at a single institution in Lima-Perú Cristian Pacheco-Román Received Received
  P-206 Prognosis of Patients Presenting as Carcinoma of Unknown Primary and Effectiveness of Acute Oncology Service: A Single Institution Experience Rajarshi Roy Received Received
  P-208 Is there a role for adjuvant chemotherapy in ypN0 disease rectal cancer patients? Rita Félix Soares Received Received
  P-209 Multicenter Real Life Experience of Biological Agents in patients with Metastatic Colorectal Cancer Duygu Cevik Received Received
  P-210 The outcomes and toxicity of FOLFIRINOX treatment in a cohort of patients with incurable pancreatic cancer treated in a single centre in Northern Ireland. Olivia Devlin Received Received
  P-211 Prognostic value of interleukin-6 in colon cancer patients: a prospective study in 60 Tunisian patients Ichrak Ben Abdallah Received Received
  P-212 Factors affecting median PFS in patients with advance, non-resectable well differentiated pancreatic neuroendocrine tumors treated initially with Octreotide LAR - real world data. . Agnieszka Kolasi&324;ska-&262;wikla Received Received
  P-213 Role of reactive oxygen species, IL-6 and KRAS mutation in rectal adenocarcinoma Luiza Serbanescu Received Received
  P-214 A single-centre experience of adjuvant oxaliplatin based chemotherapy in elderly stage II-III colorectal cancer patients Hannah Reed Received Received
  P-215 Phase 2 HEPANOVA study of tumor treating fields (TTFields, 150 kHz) concomitant with sorafenib in advanced hepatocellular carcinoma (HCC): Interim safety analysis Chelsea Higgins Received Received
  P-216 Incidence and trends of biliary tract cancer in Girona: A population-based study from the Girona Cancer Registry (1994-2016) Adelaida García Velasco Received Received
  P-217 Value of liquid biopsy using high-affinity plasma DNA binding magnetic beads and qualitative real-time PCR for KRAS, NRAS and BRAF mutations in metastatic colorectal cancer patients Jessica Lucchetti Received Received
  P-219 Clear cell variant of hepatocellular carcinoma (HCC-CC): a single-center observational study of an uncommon subtype Francesca Salani Received Received
  P-220 Management of colorectal cancers: improving clinical management of patients with MSI-high disease through education KINJAL PARIKH Received Received
  P-221 Clinical and pathological characteristics of patients with gastrointestinal neuroendocrine tumors in the United States Dina El-Habashy Received Received
  P-222 Primary malignant tumors of the small intestine: Clinical and therapeutic aspects SOUMIA BERRAD Received Received
  P-223 Prognostic role of inflammatory biomarkers in patients with advanced pancreatic adenocarcinoma undergoing first-line chemotherapy George Papaxoinis Received Received
  P-224 Improving the management of patients with pancreatic cancer: Education from treatment to adverse events and coordination of care KINJAL PARIKH Received Received
  P-225 KRAS codon 12 and 13 mutations in metastatic colorectal cancer: Predictive marker in first-line bevacizumab-based chemotherapy Tatiana Cunha Pereira Received Received
  P-226 Analysis of Hispanic Latino American Patients with Colorectal Cancer, Clinical Features and Laterality as a Prognosis Factor of Overal Survival Calderillo-Ruiz German Received Received
  P-227 Prognostic and predictive factors of platinum-based chemotherapy in gastroenteropancreatic neuroendocrine neoplasms G3 Agnieszka Kolasi&324;ska-&262;wikla Received Received
  P-228 SGNLVA-005: Open-label, phase 2 study of ladiratuzumab vedotin (LV) for aerodigestive tract malignancies William Losin Received Received
  P-229 Elderly population do benefit from adjuvant chemotherapy in gastric cancer: Experience in a single institution Cristian Pacheco-Román Received Received
  P-232 Clinical Outcomes and Characteristics According to Localization of Colorectal Cancer In Fundacion Santa Fe De Bogota Between May 2015- May 2019 Luis Pino Received Received
  P-233 Metformin combined with irinotecan in patients with refractory colorectal cancer: A phase 2 trial Raphael L. Araujo Received Received
  P-234 A SEER based analysis of clinical characteristics and survival in patients with functional endocrine tumors of gastrointestinal origin Apoorva Jayarangaiah Received Received
  P-235 Management of constipation associated with advanced cancers, chemotherapy and opioid-induced constipation by oral herbal supplement in heterogeneous group of gastrointestinal, hepatobiliary and pancreatic cancers Anandrao Patil Received Received
  P-236 New polyclonal antibody therapeutic to treat esophageal adenocarcinoma and Barretts esophagus by targeting EPHB4 Pablo GarciaValtanen Received Received
  P-237 Impact of adjuvant chemotherapy in poorly cohesive gastric carcinoma: Experience from the Peruvian National Cancer Institute Mariana Serrano Received Received
  P-239 Patient-reported outcomes in patients with metastatic gastric and esophageal cancers near end-of-life Atul Batra Received Received
  P-240 Anal cancer treatment: Major reduction of acute toxicity with an approach using 4-fractions-per-week Cam Nguyen Received Received
  P-241 First- and Second-Line treatment With Tyrosine Kinase Inhibitors After Chemoembolization In Intermediate-Stage Hepatocellular Carcinoma Patients Dimitrios Dimitroulopoulos Received Received
  P-242 Germline mutations identified in Colombian patients with Lynch syndrome John Jairo Suarez Olaya Received Received
  P-243 Incidence and survival of pancreatic neuroendocrine tumours in Girona, Spain Raquel Guardeño Sánchez Received Received
  P-244 Demographic Data, Risk Factors, and Clinical Aspects of Hepatocellular Carcinoma (HCC) in Southeastern Europe During the Last Decade Dimitrios Dimitroulopoulos Received Received
  P-245 GETNET-SILVELUL Study: An original or modified Immunohistochemical Score (IPS or mIPS) in Patients (pts) with Pancreatic Neuroendocrine Tumors (PanNET) Treated with Everolimus or CAPTEM Antonio Viudez Received Received
  P-246 Taxane cross-resistance: An exploratory analysis of second-line chemotherapy for metastatic gastric cancer Paola Di Nardo Received Received
  P-247 Real-world clinical outcomes for third-line standard of care regimens in deficient mismatch repair or microsatellite instability-high metastatic colorectal cancer in France. Romain Cohen Received Received
  P-248 Quality of life among Tunisian gastrointestinal cancer patients undergoing chemotherapy Ennouri Sana Received Received
  P-249 Resecting the unresectable: Superior survival of triple modality pancreatic adenocarcinoma patients Yang Jian Ong Received Received
  P-250 Significance of microsatellite instability PCR evaluation for metastatic colorectal cancer patients: Dynamic changes during disease course (preliminary results) Petrova Veneta Received Received
  P-251 Diversity of Helicobacter pylori genotypes in tumoral, adjacent and antral tissue of Colombian patients with gastric cancer Alix Guevara Received Received
  P-252 Serial cytokines as potential predictive/prognosis biomarkers in potentially resectable pancreatic adenocarcinoma Iranzu Gonzalez Received Received
  P-254 An experience of two Croatian centers in the treatment of gastroenteropancreatic neuroendocrine neoplasms with long-acting octreotide treatment Borislav Belev Received Received
  P-255 Effects of tumor treating fields (150 kHz) in combination with FOLFOX on gastric cancer cells in vitro Adi Haber Received Received
  P-256 Survival rates of locally advanced and metastatic pancreatic cancer in Western Australia Yang Jian Ong Received Received
  P-257 Deep Polychromatic Flow Cytometry Characterization of Circulating Endothelial Cells in Metastatic Colorectal Cancer Patients Davide Brocco Received Received
  P-258 Evaluation of volumetric modulated arc therapy with simultaneous integrated boost in carcinoma of the anal canal Mariacarla Valli Received Received
  P-259 Pembrolizumab as second-line therapy of hepatocellular carcinoma: A cost-effectiveness analysis Sik Kwan Chan Received Received
  P-260 Nave indirect treatment comparison of PanCO, a pilot study of OncoSil P-32 microparticles combined with gemcitabine nab-paclitaxel or FOLFIRINOX chemotherapy versus standard-of-care treatment in unresectable locally advanced pancreatic cancer David Turner Received Received
  P-261 Safety and effectiveness of tumor treating fields combined with sorafenib in preclinical models of hepatocellular carcinoma Adi Haber Received Received
  P-262 Effect of neoadjuvant chemotherapy in patients with gastric cancer: A retrospective study behourah zoubida Received Received
  P-263 The role of biologic targets in metastatic colorectal cancer in non-elderly patients: A single institutional analysis Marta Peixoto Received Received
  P-264 Clinical validation of next-generation sequencing as a liquid biopsy for the monitoring of patients with metastatic colorectal cancer Myrto Kastrisiou Received Received
  P-265 The study of mutations of the KRAS, NRAS, and BRAF genes in patients with colorectal cancer depending on gender, age, race in the population of the Republic of Kazakhstan Yelena Ukolova Received Received
  P-266 LDH levels as predictors of efficacy in second-line treatment for metastatic gastric cancer: the LINE study Anna Michelotti Received Received
  P-267 Signet-Ring Cell Carcinoma of the Colon: 10-Case Experience of the Medical Oncology Department at Hassan II University Hospital SOUMIA BERRAD Received Received
  P-268 Diabetes and risk of pancreatic cancer Alaeddine SAIDI Received Received
  P-269 Lenvatinib in hepatocellular carcinoma: QoL surveys and radiological imaging markers predicting clinical outcome in patients with hepatocellular carcinoma treated with lenvatinib as first-line treatment (SULENVA-HCC) Nicoletta Zanaletti Received Received
  P-270 Early tumor shrinkage as a predictor of favorable outcomes in patients with unresectable metastatic colorectal cancer treated with first-line chemotherapy plus bevacizumab behourah zoubida Received Received
  P-271 Meta-analyses on mutation status concordance between tumor tissue and circulating tumor DNA (ctDNA) and prognostic value of ctDNA in pancreatic cancer (PC) Anna Popova Received Received
  P-272 Sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy Chiara Maddalena Received Received
  P-273 Real-world experience of definitive chemoradiation in esophageal cancer: Correlation of tumour length, toxicity and disease control Rajarshi Roy Received Received
  P-274 RELEVANT study: Patient and physician perspectives on clinically-meaningful outcomes in advanced pancreatic ductal adenocarcinoma Rille Pihlak Received Received
  P-275 Quality of life and symptoms in patients undergoing CRS-HIPEC with or without perioperative systemic treatment for colorectal peritoneal metastases: results from the randomised CAIRO6 trial Checca Bakkers Received Received
  P-276 Neutrophil/lymphocyte ratio (NLR) predicts survival after curative treatments for rectal cancer patients Edna Darlene Rodrigues Pinto Received Received
  P-277 Epidemiology of pancreatic cancer: Experience of the medical oncology department of CHU HASSAN II fez hayat Erraichi Received Received
  P-278 Neutrophil-to-lymphocyte, lymphocyte-to-monocyte and platelet-to-lymphocyte ratios as predictive markers of pathological response to FLOT neoadjuvant strategy in locally advanced gastric/gastroesophageal junction cancer Tiago Cruz Tomás Received Received
  P-279 Clinical utility of circulating tumor DNA (ctDNA) in resectable and advanced pancreatic cancer (PC) Anna Popova Received Received
  P-280 The comparison of mFOLFOX-6, mDCF, mFOLFIRINOX in the first-line treatment of advanced gastric cancer Ekaterina Ignatova Received Received
  P-281 Colon Cancer in Elderly Patients: Experience of the Medical Oncology Department of CHU HASSAN II Fez hayat Erraichi Received Received
  P-282 Long-term outcomes after neoadjuvant chemoradiotherapy and R0 resection in ESCC : A propensity-matched analysis of PF versus CROSS regimen Ka-On Lam Received Received
  P-283 Analysis of KRAS mutation allele in circulating cell-free DNA derived from urine in colorectal cancer patients Ryo Ohta Received Received
  P-285 Therapeutic management of exocrine pancreatic cancer in elderly patients Alaeddine SAIDI Received Received
  P-288 Nerve fibers in the tumour microenvironment are co-localized with tertiary lymphoid structures and is associated with better survival in pancreatic cancer patients Lara Heij Received Received
  P-289 Role of the neoadjuvant chemoradiotherapy in esophageal cancer: Our centers experience Tanny Barreto Received Received
  P-291 Retrospective comparison efficacy and toxicity FOLFIRI plus aflibercept or bevacizumab in patients with metastatic colorectal cancer: Results of the multicenter observational study Mikhail Fedyanin Received Received
  P-292 Locally advanced esophageal cancer: Pattern of care, treatment outcomes and prognostic factors over a 20-year experience at the Modena Cancer Centre Fabio Canino Received Received
  P-293 Overall survival according to mutation frequency of BRAF, NRAS genes, and MSI status in patients with wild-type KRAS metastatic colorectal cancer treated with cetuximab Raphael L. Araujo Received Received
  P-294 Incorporating genetic counseling service into the gastrointestinal tumor board: Experience, obstacles, and opportunities in a Mexican center Guillermo Pacheco Cuellar Received Received
  P-295 Patterns of failure following neoadjuvant and definitive radiation strategies in carcinoma thoracic esophagus: Do we need to rethink targets? Farhan Ahmad Received Received
  P-296 Chemosensitivity and Outcome in Advanced And Metastatic Gastric Signet-Ring Cell Carcinoma (GSRC) Priscila Nejo Received Received
  P-298 Surgical resection of primary tumor as a prognostic factor in stage IV colon adenocarcinoma Kanika Nair Received Received
  P-299 Cytoreductive surgery with gastrectomy and HIPEC for gastric cancer with limited peritoneal metastases treated with neodjuvant systemic therapy is feasible and safe Maria Isabel Ramos Received Received
  P-300 Overall survival with single vs multi-agent chemotherapy in stage IIIA colon adenocarcinoma Kanika Nair Received Received
  P-301 Gastrointestinal stromal tumors: 10 years of experience in the medical oncology department at Mohammed VI university hospital in Marrakech, Morocco mohamed kaakoua Received Received
  P-302 Prognostic factors in stage IV appendiceal adenocarcinoma Kanika Nair Received Received
  P-303 Definitive radiation for esophageal cancer: Experience of a Portuguese cancer center Bárbara de Castro Received Received
  P-304 Effectiveness and safety of thermal ablation of pulmonary metastases in patients with colorectal cancer Nishanthi Silva Received Received
  P-305 Efficacy and safety of IMATINIB in gastrointestinal stromal tumors: Experience of the medical oncology department of the CHU Hassan II of FES Nouiakh Lamyae Received Received
  P-307 Colorectal cancer in young people under 45: Experience of the medical oncology service of the Hospital Hassan II of FEZ Nouiakh Lamyae Received Received
  P-309 Correlation between baseline CEA levels and TNM stage at presentation in colorectal cancers in an Indian population Venkata pradeep babu koyyala Received Received
  P-311 Low Risk of Advanced Neoplasms for up to 20 Years after Negative Colonoscopy:Potential for Personalized Follow up Screening Intervals Thomas Heisser Received Received
  P-312 Perioperative Chemotherapy Versus Surgery Alone on Resectable Advanced Gastric Cancer in a Moroccan Population siham Lalaoui Rachidi Received Received
  P-313 Management of frail patients with metastatic pancreatic ductal adenocarcinoma: A single-institution experience Andrea Plaja Salarich Received Received
  P-314 Supine VMAT versus prone 3D-EBRT in preoperative rectal cancer: Dosimetric comparison and pathological response with each radiotherapy technique Laura Diaz Received Received
  P-315 Impact of tumor location (right vs left) as a prognostic and predictive factor in colon cancer in a Moroccan population: A single-center study Nada Benhima Received Received
  P-317 Survival outcomes among patients with locally advanced esophageal cancer treated within a multidisciplinary gastro-esophageal cancer functional unit Andrea Plaja Salarich Received Received
  P-318 Survival outcomes among patients with locally advanced gastric cancer treated within a multidisciplinary gastro-esophageal cancer functional unit Angelica Ferrando Díez Received Received
  P-320 Genetic testing for microsatellite instability and KRAS mutation in stage IV colorectal cancer: Trends and outcomes from the National Cancer Database. Johannes Uhlig Received Received
  P-321 The voice beyond the clinic: Delineation of young-onset cancer patient profiles using a digital social network Ilit Turgeman Received Received
  P-322 Nutritional intervention impact on body mass index and toxicities related to 1st-line metastatic colorectal cancer treatment with targeted therapy David da Silva Dias Received Received
  P-323 RAS mutations in metastatic colorectal cancer in central Tunisia Melliti Rihab Received Received
  P-324 Advanced hepatocellular cancer: current systemic treatment sequencing and outcomes in the United States Johannes Uhlig Received Received
  P-325 EDP1503 induces anti-tumor responses via gut-mediated activation of both innate and adaptive immunity Loise Francisco-Anderson Received Received
  P-326 Chemoradiotherapy treatment in gastroesophageal junction tumors Jesica Storino Received Received
  P-328 Biliary tract cancers: Epidemiology and trends in Tunisian patients Ichrak Ben Abdallah Received Received
  P-331 Adjuvant chemotherapy for stage II colon cancer following complete resection: Experience of the Mohammed VI University Hospital Centre oncology center in Marrakech kawtar El bouaouidi Received Received
  P-332 Real world data (RWD) study of BRAF mutant metastatic colorectal cancer (mCRC) patients (pts) across the Greater Manchester region prior to BEACON trial results Rory Cairns Received Received
  P-334 Perioperative chemotherapy in the treatment of resectable and locally advanced gastric and junctional esophagogastric adenocarcinoma: Experience of a Portuguese central hospital Ema Neto Received Received
  P-335 Self-reported prescribing practices in the setting of adjuvant treatment for colorectal cancer Catherine Hanna Received Received
  P-336 Clinical outcomes of 49 consecutive patients admitted with malignant obstructive jaundice Syed Abdullah Javaid Bukhari Received Received
  P-338 Advanced pancreatic adenocarcinoma in daily clinical practice: A single-center experience Alaeddine SAIDI Received Received
  P-339 Real-world data (RWD) of the use of trifluridine/tipiracil hydrochloride (TFT) in patients with metastatic colorectal cancer: The Greater Manchester experience Alia Alchawaf Received Received
  P-341 Capecitabine/mitomycin versus 5-fluorouracil/mitomycin in combination with simultaneous integrated boost-intensity modulated radiation therapy for anal cancer Léa Vazquez Received Received
  P-342 Margetuximab combined with anti-PD-1 (MGA012) or anti-PD-1/LAG-3 (MGD013) /- chemotherapy in first-line therapy of advanced/metastatic HER2 gastroesophageal junction or gastric cancer Minori Rosales Received Received
  P-344 The role of postoperative prognostic nutritional index as a prognostic factor and its association to systemic inflammatory response markers in stage III colon cancer Ins Costa Received Received
  P-345 Evaluation of a fully automated Idylla test system for microsatellite instability in a cohort of Spanish patients with colorectal carcinoma in a single institution Miriam Perez García Received Received
  P-346 Endoscopic Profiling of Various GI Malignancies in CMOSH Medical College Hospital, Chattogram, Bangladesh Debashis Chowdhury Received Received
  P-347 A phase 3, randomized, double-blind, placebo-controlled study of transarterial chemoembolization combined with durvalumab or durvalumab plus bevacizumab therapy in patients With locoregional hepatocellular carcinoma: EMERALD-1 Bruno Sangro Received Received
  P-348 A multi-institutional retrospective study of stage I-IV transverse colon cancer: Diagnosis, treatment and outcome analyses Francesca Lo Bianco Received Received
  P-349 Clinical significance of lymph node radio to predict prognosis in colon cancer Gyoung Tae Noh Received Received
  P-350 Maintenance Trastuzumab in the setting of second line treatment in HER2 overexpressing metastatic gastric and gastroesophageal junction adenocarcinoma: a single center experience López López Flora Received Received
  P-351 RNA sequencing for personalized therapy prescription in colon cancer Elena Poddubskaya Received Received
  P-353 Colorectal cancer liver metastases challenges and potential opportunities: Systematic review and meta-analysis Ereny Saad Received Received
  P-354 Association Between Tumor Regression with Tumor Location and Inflammatory Biomarkers in Patients with Resectable Gastric Cancer and Gastroesophageal Junction Cancer who Underwent Perioperative Chemotherapy: Multicentric Data from Peru Rodrigo Motta Received Received
  P-355 Trastuzumab-based treatment of HER2-positive metastatic gastric cancer &304;zzet Do&287;an Received Received
  P-356 Phase Ib study of irinotecan, bevacizumab and biweekly trifluridine/tipiracil in patients with metastatic colorectal cancer refractory to fluoropyrimidine and oxaliplatin: Preliminary report of MODURATE study Kentaro Yamazaki Received Received
  P-357 The Frequencies and Prognostic Significance of ABO Blood and Rhesus (D) Groups in HER2-Positive Gastric Cancer &304;zzet Do&287;an Received Received
  P-358 Mutational status in Ras/Raf/MAPK signaling pathway in Moroccan colorectal cancer patients Mohammed Sqalli Houssaini Received Received
  P-359 Biliary tract carcinoma: Management patterns and outcome Ryma Boujnah Received Received
  P-360 EGFR-inhibitors in metastatic wild-type RAS colorectal cancer: Experience of the oncology department of Mohammed VI University Hospital in Marrakech houda jouihri Received Received
  P-361 High expression levels of circulating miRNA-618 and miRNA-203a-3p are associated with prolonged survival in patients with metastatic colon cancer Maria Radanova Received Received
  P-362 SIBO and lactose intolerance in patients receiving chemotherapy treatment for colorectal or gastric cancer Nora Forones Received Received
  P-363 Clinical - Pathological Correlation of The Presence of Microsatellite Instability in Patients Diagnosed with Locally Advanced Gastric Adenocarcinoma from Costa Rica Alejandra Méndez Received Received
  P-364 Higher amount of KRAS mutations in pre-operative plasma cell-free DNA predicts shorter survival after liver metastasectomy in colorectal cancer patients Jiri Polivka Received Received
  P-365 Association between baseline serum levels of miRNA-143 and hepatocyte growth factor in patients with RAS wild type metastatic colorectal cancer treated with first-line anti-EGFR therapy Zhasmina Mihaylova Received Received
  P-366 Long-term quality of life in patients treated for anal cancer: Self-reported bother of symptoms Anna Axelsson Received Received
  P-367 A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries Omkara Veeranki Received Received
  P-368 Primary tumor location in synchronous and metachronous liver metastases: Impact on patterns of recurrence and survival after hepatic resection Rita Balsano Received Received
  P-369 Quality of life of caregivers of patients with gastrointestinal cancer Nora Forones Received Received
  P-372 Safe moderate dose regimens retain full survival benefits for aged patients with and without resistant gastrointestinal cancers Robert De Jager Received Received
  P-373 Moderate Dose Chemotherapy Retains Efficacy and Improves Safety in Conjunction with High Dose Ascorbic Acid (HDAA) Howard Bruckner Received Received
  P-384 Quality of life and systemic pharmacokinetics of repetitive electrostatic PIPAC with oxaliplatin in patients with colorectal peritoneal metastases Robin Lurvink Received Received
  P-385 A phase 1/2 study of combination therapy of ivaltinostat, gemcitabine, and erlotinib in patients with unresectable, locally advanced and metastatic pancreatic adenocarcinoma Jung Hyun Jo Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
07:26
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments
Captcha image
 

ESMO WORLD CONGRESS ON GASTROINTESTINAL CANCER

ESMO 22nd World Congress on Gastrointestinal Cancer

 

1-4 July 2020 Barcelona
HELP LINE
Manage Orders
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 01/07/2020 TO 01/07/2021
Poster
Gallery
Oral Presentation
& Video Gallery
Poster Discussion
Forum
                  
PrintingOnline
Submit your poster online
in powerpoint format

   Poster submission deadline 29/06/2020
Upload Poster
Upload Oral Presentation of Video
Upload
Poster
Upload Oral
Presentation or Video




PosterSessionOnline
Logo Draft
 
Logo Cert